<DOC>
	<DOCNO>NCT02578368</DOCNO>
	<brief_summary>Previously untreated patient limited metastatic stage ( see protocol detail criterion ) receive 4 cycle FLOT ( 5-Fluorouracil , Leucovorin , Oxaliplatin Docetaxel ) . Patients without disease progression randomize 1:1 receive additional chemotherapy cycle ( 4-8 cycle FLOT ) surgical resection follow subsequent chemotherapy ( 4-8 cycle FLOT ) . Main objective study overall survival . Most important secondary objective quality life treatment follow-up .</brief_summary>
	<brief_title>Chemotherapy Alone v . Chemotherapy + Surgical Resection Patients With Limited-metastatic Adenocarcinoma Stomach Esophagogastric Junction</brief_title>
	<detailed_description>Patients potentially limited metastatic gastric cancer adenocarcinoma gastroesophageal junction ( GEJ ) potentially fulfil selection criterion give inform consent undergo careful screening central review process . 271 patient allocated trial , least 176 patient randomize . The primary objective extend overall survival , preserve quality life . The study 80 % power detect statistically significant improvement ( hazard ratio , HR 0.65 ) overall survival favor bimodal strategy . Quality life ( QoL ) treatment follow-up represent important secondary endpoint . All patient enrol receive four cycle ( = 8 week ) FLOT . For HER-2 ( human epidermal growth factor receptor 2 ) positive disease , trastuzumab add . After 4th cycle FLOT , patient undergo repeat imaging ( esophago-gastro-duodenoscopy , CT/MRI PET scan involved organ ) . Patients disease progression take trial . Patients stable disease , partial complete remission stratify tumor location ( gastric vs. GEJ adenocarcinoma ) , response preoperative FLOT ( complete partial remission vs. stable disease ) base whether distant lymph node metastases additional organ involvement randomize 1:1 Arm A ( surgery ) B ( surgery ) . Arm A : Surgery schedule 4-6 week d1 last cycle preoperative chemotherapy ( d1 + 4-6 week ) . The protocol give detailed recommendation resection primary tumor well metastasis . Post-operatively , 4-8 cycle FLOT administer . Arm B : Patients treat additional 4-8 cycle FLOT . Surgical intervention allow palliation . In arm , tumor assessment ( CT/MRI PET relevant organ ) perform prior randomization every 3 month thereafter progression/relapse , death end follow-up . Quality life ( QoL ) assess baseline , prior randomization , every 3 month randomization treatment follow-up phase , together tumor assessment . Survival status status relapse/first progress disease assess every 3 month 5 year randomization .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>1 . Histologically confirm limited metastatic gastric GEJ adenocarcinoma . * 2 . Medical technical operability primary . 3 . Metastatic lesion resectable control local ablative procedure ( central evaluation ) . 4 . No prior chemotherapy prior tumor resection . 5 . Female male patient ≥ 18 year . Patients reproductive age must willing use adequate contraception study 3 month end study ( appropriate contraception define surgical sterilization ( e.g. , bilateral tubal ligation , vasectomy ) , hormonal contraception ( implantable , patch , oral ) , doublebarrier method ( double combination : intrauterine device , male female condom spermicidal gel , diaphragm , sponge , cervical cap ) ) . Female patient childbearing potential need negative pregnancy test within 7 day study start . 6 . ECOG ( Eastern Cooperative Oncology Group ) Performance Status 0 1 7 . Adequate hematological , hepatic renal function parameter : Leukocytes ≥ 3000/µl Platelets ≥ 100,000/µl Serum creatinine ≤ 1.5 x upper limit normal , glomerular filtration rate ( GFR ) &gt; 40 ml/min Bilirubin ≤ 1.5 x upper limit normal AST ( aspartate aminotransferase ) ALT ( alanine transaminase ) ≤ 3.5 x upper limit normal Alkaline phosphatase ≤ 6 x upper limit normal 8 . Written informed consent patient . ( * ) Definition limit metastatic status : 1 . Retroperitoneal lymph node metastasis ( RPLM ) ( e.g. , paraaortal , intraaortocaval , parapancreatic mesenterial lymph node ) ( Note : duodenum invade gastric cancer , retropancreatic node regard M1 ) or/and 2. maximum one organ involve without RPLM accord follow schema : I . Localized potentially operable peritoneal carcinomatosis : stage P1 accord classification `` Japanese Research Society Gastric Cancer '' ( Clinically visible carcinomatosis peritoneum pleura &gt; P1 peritoneal carcinomatosis allow ! ) II . Liver : maximum 5 metastatic lesion potentially resectable III . Lung : unilateral involvement , potentially resectable IV . Uni bilateral Krukenberg tumor ( ovarian met . ) absence macroscopic peritoneal carcinomatosis V. Uni bilateral adrenal gland metastasis VI . Extraabdominal lymph node metastases supraclavicular cervical lymph node involvement VII . Localized bone involvement ( define within one radiation field ) VIII . Other metastatic disease location consider limited investigator confirm review committee 1 . Medical inoperability 2 . Inability understand aim study and/or protocol procedure 3 . Metastatic disease fulfil criterion limited disease mention inclusion criterion nonmetastatic stage ( cM0 ) 4 . Cirrhosis liver , pronounce alcohol abuse anticipated detoxification , severe pulmonary infection considerable reduction pulmonary function 5 . Primary resectable 6 . Hypersensitivity 5fluorouracil , leucovorin , oxaliplatin , docetaxel , trastuzumab ( HER2 positive tumor ) 7 . Contraindication versus 5fluorouracil , leucovorin , oxaliplatin , docetaxel ( see specific product information ) , trastuzumab ( HER2 positive tumor ) 8 . Clinically significant active coronary heart disease , cardiomyopathy congestive heart failure , NYHA ( New York Heart Association ) IIIIV 9 . Clinically significant valvular defect 10 . Past current history malignancy unless curatively treat without evidence disease 3 year , except curatively treat basal cell carcinoma skin situ carcinoma cervix 11 . Known brain metastasis 12 . Other severe internal disease acute infection 13 . Peripheral polyneuropathy &gt; NCI grade II 14 . Serious hepatic impairment ( AST/ALT &gt; 3.5xULN , AP &gt; 6xULN , bilirubin &gt; 1.5xULN ; ULN = upper limit normal ) 15 . Chronic inflammatory bowel disease 16 . Any concurrent antineoplastic treatment include irradiation 17 . Participation another clinical study 18 . Pregnancy lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>gastric cancer</keyword>
	<keyword>perioperative</keyword>
	<keyword>FLOT</keyword>
	<keyword>limited metastatic</keyword>
	<keyword>GEJ cancer</keyword>
</DOC>